As Encodia's Chief Technology Officer, Dr Beard leads a talented and innovative team to develop and scale the product portfolio. Dr. Beard has a 20+ year track record of bringing transformative life sciences products to market. Experienced in strategic technology development raising over +$100M venture capital in cutting edge genomics, machine learning and 3D printing technologies that focused on precision and personalized products from consumer to multiomic platforms aimed at eradicating cancer. Most recently served as CTO and Senior Vice President (SVP) of Operations at Mission Bio, where he launched and scaled Tapestri, a platform for multiomic single cell analysis. Prior to that, he served as Chief Operating Officer (COO) and CTO at Feetz, Inc. He also held R&D leadership positions for Applied Biosystems and Life Technologies, managing $100M's in R&D spend for +1,500 scientists. He is an inventor on over 50 patents, launched over 40 products, and serves as an advisor/board member for other start-up companies.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.